Sign up
Pharma Capital

ANGLE raises another £2.8mln

The further subscription has been announced to accommodate an investor who wasn’t able to get the necessary paperwork completed to take part in last week’s fundraising
pound coins and pound notes
The additional investment will help to boost the balance sheet

Liquid biopsy company ANGLE PLC (LON:AGL) has raised an additional £2.8mln after it agreed to let an investor subscribe additional shares.

ANGLE raised £12.2mln last week and the investor wanted to take part in that fundraising but “due to the compact timelines” wasn’t able to complete the necessary paperwork in time.

READ: ANGLE raises £12.2mln; completes acquisition of complementary IP

The terms are the same as the original subscription, with the AIM-quoted firm issuing 7.5mln shares at a price of 37.5p each.

"This further subscription will give the company a stronger balance sheet, which will provide flexibility to both target relevant investment and assist the company in pursuing commercial partnerships for both ParsortixTM and the assets to be acquired from Axela,” said chief executive Andrew Newland.

READ: ANGLE continues to make progress with Parsortix

Of the money raised last Thursday, roughly £3.7mln of it went towards the acquisition of some assets from Axela – a Canadian company with intellectual property that complements ANGLE’s Parsortix liquid biopsy platform.

View full AGL profile

ANGLE plc Timeline

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.